<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03790800</url>
  </required_header>
  <id_info>
    <org_study_id>INTERACT4</org_study_id>
    <nct_id>NCT03790800</nct_id>
  </id_info>
  <brief_title>Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial</brief_title>
  <acronym>INTERACT4</acronym>
  <official_title>Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute for Global Health, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chengdu Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute for Global Health, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, ambulance-delivered, prospective, randomized, open-label, blinded endpoint
      (PROBE) study to assess the effects of pre-hospital blood pressure (BP) lowering initiated in
      ambulance setting on (i) hematoma volume at 24 hours in patients with confirmed intracerebral
      haemorrhage (ICH), and (ii) safety in patients with confirmed acute ischaemic stroke and
      other conditions that were initially suspected as acute stroke (i.e. stroke mimic)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As an investigator initiated and conducted, multicentre, ambulance-delivered, prospective,
      randomised, open-label, blinded outcome (PROBE) study. INTERACT4 aims to evaluate the effects
      of pre-hospital BP lowering initiated in ambulance settings on haematoma volume at 24 hours
      in ICH patients, the time to and rate of reperfusion treatment (thrombolysis and/or
      thrombectomy) in those with acute ischemic stroke, and functional outcomes at 90 days and
      safety in all participating patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>haematoma volume</measure>
    <time_frame>Day 1</time_frame>
    <description>In cases of confirmed intracerebral haemorrhage (ICH), haematoma volume measured on brain CT scan at 24 hours after stroke onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haematoma volume at presentation</measure>
    <time_frame>Day 0</time_frame>
    <description>In cases of confirmed intracerebral haemorrhage (ICH), haematoma volume measured on brain CT scan at admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional recovery</measure>
    <time_frame>Day 90</time_frame>
    <description>measure of disability on the modified Rankin scale (mRS), where scores range from 0 (no symptoms) to 6, with a score of 0 and 1 indicating no or some symptoms, respectively, 2-5 indicate increasing levels of disability/dependency, and 6 death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral infarct size</measure>
    <time_frame>Day 2</time_frame>
    <description>cerebral infarct size on MRI within 2 days in patients with acute ischaemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reperfusion treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>frequency of reperfusion treatment (thrombolysis and/or thrombectomy) in all confirmed acute ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reperfusion treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>time from stroke onset to reperfusion treatment in those patients who undergoing from from symptom onset to the time of reperfusion (thrombolysis and/or thrombectomy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reperfusion treatment related symptomatic intracerebral hemorrhage</measure>
    <time_frame>Day 7</time_frame>
    <description>symptomatic intracerebral hemorrhage according to standard measure after reperfusion treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in hematoma volume</measure>
    <time_frame>Day 1</time_frame>
    <description>hematoma volume growth from baseline to 24 hours, measured on brain imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If systolic blood pressure&gt;180:IV Urapidil 25mg If systolic blood pressure&gt;150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is &gt;220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>urapidil</intervention_name>
    <description>A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists &gt;150 after 5 minutes.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Intensive BP lowing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age ≥18 years;

          2. Acute syndrome that is due to presumed acute stroke, defined as FAST（Face, Arm,
             Speech, Time） scores of ≥2 with an arm motor deficit and time ≤2 hours from last seen
             well;

          3. Systolic BP ≥150

          4. Able to provide brief informed consent (if a waver of consent is not approved by the
             ethics committee)

        Exclusion Criteria:

          1. Coma - no response to tactile stimuli or verbal stimuli;

          2. Severe co-morbid disease (e.g. cancer, chronic airflow disease, severe heart failure);

          3. History of epilepsy or seizure at onset;

          4. History of recent head injury (&lt;7 days);

          5. Known definite contraindication to an intensive BP lowering regimen (eg severe
             carotid, vertebral or cerebral arterial stenosis, known MoyaMoya disease or Takayasu's
             arteritis, high-grade stenotic valvular heart disease, or severe renal failure);

          6. Known advanced dementia or significant pre-stroke disability (eg mRS scores 3-5);

          7. A high likelihood that the patient will not adhere to the study treatment and
             follow-up regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Anderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute for Global Health, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lily Song</last_name>
    <phone>+86 13916466400</phone>
    <email>lsong@georgeinstitute.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lily Song</last_name>
      <phone>+86 13916466400</phone>
      <email>lsong@georgeinstitute.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Feifeng Liu</last_name>
      <phone>+86 15121100573</phone>
      <email>liufeifeng7@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2019</study_first_posted>
  <last_update_submitted>December 29, 2018</last_update_submitted>
  <last_update_submitted_qc>December 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The George Institute for Global Health, China</investigator_affiliation>
    <investigator_full_name>Craig Anderson</investigator_full_name>
    <investigator_title>Executive Director</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>blood pressure control</keyword>
  <keyword>hypertension</keyword>
  <keyword>clinical trial</keyword>
  <keyword>ambulances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urapidil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with bona fide researchers after 1 year following conclusion of the study, based on a submitted protocol to the research office of The George Institute for Global Health, Sydney Australia</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year after conclusion of the study</ipd_time_frame>
    <ipd_access_criteria>genuine researcher with supporting institution protocol review and approval by the research office of The George Institute</ipd_access_criteria>
    <ipd_url>http://georgeinstitute.org.au</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

